Moxifloxacin Vioser (Moxifloxacin Hydrochloride)

Moxifloxacin hydrochloride inhibits bacterial DNA gyrase and topoisomerase IV, enzymes that control DNA supercoiling and replication. By binding to these targets, the drug prevents bacterial DNA synthesis and transcription, leading to bacterial cell death across a wide range of Gram‑positive, Gram‑negative and atypical organisms.

The specific dose and infusion rate of Moxifloxacin Vioser are determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and local guidelines. Healthcare professionals should follow the product label and institutional protocols.

Safety data for moxifloxacin in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician in consultation with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Moxifloxacin offers a broader spectrum against Gram‑positive and atypical pathogens compared with older fluoroquinolones such as ciprofloxacin. It also has a higher potency against respiratory organisms, but shares class‑related safety considerations like QT prolongation and tendon toxicity, which must be weighed against alternative agents.

Moxifloxacin Vioser should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Maintaining the cold chain preserves drug stability and potency until the point of administration.

The product is supplied as an intravenous solution for infusion. It is administered by a qualified healthcare professional through a peripheral or central venous line, following aseptic technique and the infusion rate recommended in the prescribing information.

Serious adverse events include tendon rupture or tendinitis, QT interval prolongation leading to potentially fatal arrhythmias, severe hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome, Clostridioides difficile‑associated colitis, and hepatic failure. Prompt recognition and discontinuation are essential if these events occur.

Patients with a known hypersensitivity to moxifloxacin or other fluoroquinolones, those with a history of tendon disorders related to fluoroquinolone use, individuals with significant QT prolongation, and patients taking medications that strongly interact to increase toxicity should avoid this drug unless no alternatives exist.